News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.
The firm plans to use the funding to drive sales of its preimplantation genetic screening tests and to invest in data science.
Illumina continues to forge partnerships with diagnostic developers overseas as it eyes approximately 50 population sequencing projects around the world.
The subsidiary is the Taiwan-based firm's first and potentially could provide it access to the genetic testing markets in Laos, Cambodia, Vietnam, and Indonesia.
Milu will help launch the test in countries including China as it works to develop a diagnostics business in Asia targeting maternal and women's health.
